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improved survival (1.7% vs. 2.7%, P  0.001). In multi-
variate analysis, stent use was not associated with a sig-
nificantly lower risk of a revascularization procedure on
readmission to the same institution [OR 0.95, 95% CI
(0.87–1.04), P  0 .28]. From the health care system’s
perspective, 106 patients would need to be treated with a
stent to prevent one death on sentinel admission. CON-
CLUSION: Stent use decreased in-patient mortality by
1% without impacting length of stay or readmission
rates. At $149,354 per life year saved, stents would need
to increase a person’s life expectancy by a minimum of
three years over that which is gained from PTCA alone to
remain a cost-effective alternative.
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Data is available on stent PTCA restenosis rates in RCTs
but little data is available on restenosis rates and medical
costs in actual practice. OBJECTIVES: To compare rest-
enosis rates (repeat PTCA or stent, coronary artery by-
pass grafting, or myocardial infarction) and medical care
costs during one year post-PTCA for patients with and
without stents. METHODS: A total of 1756 patients
with index PTCA during 1995 and no PTCA in the prior
1 year were identified from a medical claims database of
large self-insured plans covering 1.7 million lives. Stents
were received by 373 of 1756 PTCA patients during the
index PTCA. RESULTS: Restenosis occurred in 316
(22.8%) of 1383 non-stent patients versus 62 (16.6%) of
373 (P  0.001) stent patients. For the one-year period
following index PTCA, ischemic heart disease (IHD)-
related medical costs were not significantly different be-
tween stent (mean  $5898,) and non-stent (Mean 
$7018) groups (P  0.18) nor did total medical costs dif-
fer among stent (Mean  $14,128) and non-stent (Mean 
$13,621) groups (P  0.71). Logistic regression (includ-
ing: age, gender, comorbidities, prior year hospitaliza-
tions, percent of IHD hospitalizations in prior year,
PTCA length of stay, and inpatient-PTCA) revealed
lower probability of restenosis (odds ratio  0.7, P 
0.02) in stent patients. Cost regressions using the same
covariates revealed no significant difference in IHD re-
lated costs or total medical costs for the one year period
following index PTCA. CONCLUSIONS: Although stented
patients had lower restenosis rates, 1-year medical costs
following PTCA were not significantly different based on
stenting.
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Inhaled agents and propofol are used to sedate patients
for surgical interventions. Economic analysis of these
agents is complex and includes acquisition cost, wastage,
adjuvants, flow rate of fresh gas, equipments, and pa-
tient-specific factors. OBJECTIVES: The study purpose
was to benchmark annual costs of halothane, isoflurane,
desflurane, sevoflurane, enflurane, thiopenthal and pro-
pofol in Canadian pediatric institutions. METHODS: A
written survey was sent to 9 major hospital pharmacy de-
partments in 1999 with 2 recalls regarding the 1997–98
and 1998–99 fiscal years. RESULTS: Response rate was
78% (7/9). Our cohort includes a total 1005 beds,
48,659 admissions/year and 64,552 surgical procedures/
year. Day surgery represents 31% of total cases. Inhaled
agents and propofol represented 47.4% (n  7, sd  8.1)
of total drug costs in operating room (OR) and recovery
room (RR). Anesthetic agents costs were on average
$0.18 CAN/min of surgery (n  4, sd  0.05) in 1997–
98 and $0.21 CAN/min (n  3, sd  0.13) in 1998–99.
Total costs/patient of all drugs used were $430.26 CAN
(n  4, sd  8.8) in 1997–98 and $26.11 CAN (n  4,
sd  6.28) in 1998–99. Total costs/patient for anesthetic
agents were $13.54 CAN (n  4, sd  2.7) in 1997–98
and $12.48 CAN (n  4, sd  1.98) in 1998–99. Costs
reduction seems to be mainly caused by price reduction
of isoflurane for 1998–99 which went from 1st position
in 1997–98 ($171,610 CAN, n  5) to 3rd position in
1998–99 ($116,700 CAN, n  5) even with a 10% in-
crease in consumption. Total costs of these agents
increased by 3.5%. Sevoflurane has taken the 1st position
in 1998–99. CONCLUSION: There are little data avail-
able in the literature to allow benchmarking in the pedi-
atric OR. Further studies are required to identify the best
ratio useful to monitor such costs as well as relevant out-
comes.
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BACKGROUND: Treatment of intra-abdominal infec-
tions (IAI) has important health economic components
including hospital stay and the cost and administration of
pharmaceuticals. METHODS: From the hospital’s per-
spective, time-to-discharge (TTD) was evaluated for 258
